Savant Capital LLC Buys 13,079 Shares of Neurocrine Biosciences, Inc. $NBIX

Savant Capital LLC boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 128.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 23,242 shares of the company’s stock after buying an additional 13,079 shares during the period. Savant Capital LLC’s holdings in Neurocrine Biosciences were worth $2,921,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NBIX. Dodge & Cox raised its holdings in shares of Neurocrine Biosciences by 83.5% in the first quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock worth $612,129,000 after buying an additional 2,518,199 shares during the period. Wellington Management Group LLP lifted its stake in Neurocrine Biosciences by 44.0% in the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock worth $232,037,000 after acquiring an additional 640,556 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Neurocrine Biosciences by 3.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company’s stock valued at $170,281,000 after purchasing an additional 49,088 shares in the last quarter. Braidwell LP boosted its position in Neurocrine Biosciences by 32.2% during the 1st quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock valued at $131,827,000 after acquiring an additional 290,135 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Neurocrine Biosciences by 8.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,159,367 shares of the company’s stock valued at $128,226,000 after purchasing an additional 89,271 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Price Performance

NBIX stock opened at $150.02 on Tuesday. The company has a market capitalization of $14.96 billion, a P/E ratio of 35.89, a price-to-earnings-growth ratio of 0.94 and a beta of 0.22. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $157.67. The firm’s fifty day simple moving average is $142.23 and its 200-day simple moving average is $131.95.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, October 28th. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.46. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same period in the previous year, the firm posted $1.81 earnings per share. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. As a group, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

NBIX has been the topic of several analyst reports. Zacks Research raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Wedbush restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, September 22nd. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Truist Financial reissued a “buy” rating and set a $172.00 price objective (up from $165.00) on shares of Neurocrine Biosciences in a report on Thursday, October 30th. Finally, Stifel Nicolaus raised their target price on Neurocrine Biosciences from $174.00 to $183.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $170.26.

Insider Activity

In other news, CEO Kyle Gano sold 300 shares of the business’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at $19,933,581.79. The trade was a 0.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William H. Rastetter sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total value of $2,732,760.00. Following the sale, the director directly owned 40,360 shares in the company, valued at approximately $6,127,455.20. This trade represents a 30.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.